ArticleAvicenna journal of phytomedicine
Almond for mild to moderate Alzheimer's disease: A randomized clinical trial.
Article in Avicenna journal of phytomedicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Effects of almond consumption on sleep quality in adults: a randomized controlled trial.Frontiers in nutrition · 2026Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Almonds are frequently advised as brain tonic and memory enhancers in Persian medicine. There is also scientific evidence to support the effects of almond on memory. This study was designed to assess the effects of almond ( Materials and Methods: In this randomized controlled trial, 60 AD patients with mild to moderate cognitive disorder were randomly allocated into an almond group (10 g/day powdered sweet almond plus 1 teaspoon of powdered rock candy along with their previous prescriptions), or the control group (continue previous prescriptions) for 3 months. The Mini-mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), Clinical Dementia Rating (CDR), and Functional Assessment Staging (FAST) questionnaires were completed at the beginning and the end of the study. The sleep quality was also assessed by the Pittsburg Sleep Quality Index (PSQI). Results: Thirty participants in each group completed the study, and were analyzed. Age was 71.86±8.04 years in the almond group and 71.3±7.18 years in the control group (p=0.775). Duration of memory deficit was 2.8±0.92 and 3±1.2 months in the almond and control group, respectively (p=0.473). The orientation scale of the MMSE (p=0.024), MOCA (p=0.001), memory scale of MOCA (p=0.005), FAST (p=0.032), and PSQI (p<0.001) in the almond group were significantly improved compared to those in the control group. Conclusion: Almond is a probable safe intervention for memory and sleep enhancement in AD patients. Conducting studies with larger samples, longer follow-up periods, and different control groups are suggested.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.